Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory to or relapsed after at least 1 prior treatment regimen;~* Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;~* At least 18 years of age.~Exclusion Criteria:~* Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks);~* Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;~* Known hepatitis B virus, hepatitis C virus or HIV infection;~* Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TGR-1202 (Type: EXPERIMENTAL): TGR-1202 Daily Oral Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).